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Abstract  
Mycobacterium tuberculosis isolates from multiple drug resistant or extensively 
drug resistant patients show a particular set of mutations in drug targets conferring 
resistance.  However, the selection of drug-resistant strains in vitro yields an alternative 
set of mutations, thought to result from the cost-benefit associated with drug resistance.  
Mutations allowing for survival under antibiotic may not be beneficial when presented 
with the host environment or with a drug-free environment.  These fitness effects drive 
the natural evolution of this bacterium.  Using recombineering a large cohort of mutations 
was generated within two drug targets, inhA and gyrA, to study in vitro the variability of 
mutations allowable under either isoniazid or ofloxacin, respectively.  As a proof of 
concept this process was carried out in Mycobacterium smegmatis.  Analysis of survivors 
allowed for identification of novel mutations and substitutions, as well as showing 
mutations previously found only in clinical isolates can be present in laboratory isolates.   
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Chapter I Introduction 
Overview 
Tuberculosis (TB) is an infectious disease concentrated primarily within the respiratory 
tract and is caused by the bacterium Mycobacterium tuberculosis (M. tuberculosis).  Once 
exposed, approximately 10% of individuals develop active disease characterized by 
cough, fever, lethargy, and weight loss (Raviglione, 2006).  Despite such a small 
percentage of individuals developing active disease, there are an estimated 1.5 million TB 
related deaths every year worldwide making it the second leading cause of death from an 
infectious disease behind HIV (WHO, 2011).  Unfortunately, this plight has become an 
even greater problem with the development of drug resistant M. tuberculosis strains.  
Some individuals are shown to have disease resistant to not just one antibiotic, but 
multiple or even all known treatments.  Multiple drug resistant tuberculosis (MDR-TB) 
patients demonstrate resistance to the first line drugs rifampicin and isoniazid (INH), 
while extensively drug resistant tuberculosis (XDR-TB) patients have MDR-TB with 
added resistance to the class of second line drugs, fluoroquinolones (FQ), and at least one 
of the second line injectable agents amikacin, kanamycin, and/or capreomycin (WHO, 
2010). 
 
Bacterial isolates from these MDR-TB or XDR-TB patients are consistently shown to 
have a particular set of mutations in drug targets conferring resistance.  However, 
spontaneous drug resistant mutants generated in the laboratory for drug resistance studies 
often yield an alternative set of mutations.  This differing spectrum of mutations hinders 
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the study of drug resistance evolution.  Without a reliable model for the evolution of drug 
resistance, more efficient anti-tubercular drugs will continue to be elusive.  Therefore, the 
cause of these variations between clinical and laboratory isolates, as well as a method to 
predict which mutations will arise needs to be explored.  
 
The cost-benefit associated with drug resistance is one explanation for this difference 
between clinical and laboratory isolates.  This cost-benefit is linked to the possibility of 
decreased function of a protein after mutation.  This is especially the case for drug 
targets, as the drug often blocks an active or binding site of an essential bacterial protein 
thereby killing the bacteria.  Therefore, mutations conferring drug resistance often alter 
the activity of the targeted protein.   
 
The environment encountered by a population of bacteria plays a major role in whether or 
not the decreased function of a vital protein would be detrimental.  For bacteria 
undergoing drug selection, the conditions in vivo and in vitro are exceedingly different.  
For instance, a protein necessary for survival when challenged by the host immune 
response would not be as necessary for a bacterium grown in culture.  It is these fitness 
effects associated with differing environmental pressure that drives the development of 
the global population of bacteria.   
 
Recombineering 
Studying the evolution of drug resistance in an in vitro environment has proven 
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problematic without satisfactory experimental alternatives accounting for these 
environment differences.  Therefore, a unique approach to the study of drug resistance 
evolution was taken, the opposite of selecting for spontaneous mutants under antibiotic 
pressure.  A large cohort of possible mutations within an antibiotic target was generated 
to study the variability of mutations allowable under antibiotic selection in vitro.  This 
mutational library was created in Mycobacterium smegmatis (M. smegmatis) through the 
use of a technique known as recombineering, to be explained in detail below.  Analysis of 
the drug susceptibility allowed for the identification of novel mutations, as well as 
showing mutations previously observed only in clinical isolates can be present in 
laboratory isolates.   
 
Genetic techniques such as homologous recombination have greatly increased the 
abilities of researchers to manipulate many model organisms, from bacteria to mice.  
However, many of these methods contain pitfalls resulting in decreased efficiency.  As is 
the case with conventional cloning, unique restriction enzymes cannot always be found, 
which is especially difficult when working with large pieces of DNA.  Additionally, large 
pieces of DNA can be fragile thereby adding another complication to working with large 
DNA molecules.  On the other hand, large DNA molecules can be accurately 
manipulated using homologous recombination.  Also, no restriction enzyme sequences 
are required; homologous recombination requires only a discrete region of homologous 
sequence.  Through the added convenience of phage mediated homologous 
recombination, termed recombineering, shorter regions of homology can be used (Court 
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Figure I.1 Accepted model for the molecular action of recombineering.   
The ring structured single stranded DNA annealing protein (SSAP) aids in annealing the mutated single 
stranded DNA oligo to the lagging strand of DNA at the replication fork (adapted from van Kessel et al., 
2008 and Murphy and Marinus, 2010). 
et al., 2002).  For instance in Escherichia coli (E. coli), only 50 nucleotides flanking the 
region to be changed need to be of homologous sequence (van Kessel et al., 2008). 
Recombineering takes advantage of the bacteriophage proteins RecE and RecT for facile 
generation of single point mutations, deletions, and insertions (van Kessel and Hatfull, 
2008).  RecE, a DNA exonuclease, creates single stranded DNA which is annealed to 
replicating DNA by RecT, a single stranded DNA annealing protein (SSAP), allowing for 
homologous recombination (Figure I.1).  This bacteriophage based system does not 
require RecA, which is advantageous due to the possibility of unwanted recombination 
events with RecA (Court et al., 2002).  With the discovery of homologous proteins in 
mycobacteriophages it became possible to perform similar experiments in mycobacteria.  
The mycobacteriophage Che9c encodes the homologous proteins gp60 and gp61, which 
were demonstrated to have biochemical similarity to RecE and RecT, respectively (van 
Kessel and Hatfull, 2007).  Fortunately, when working with single stranded DNA 
(ssDNA) only the RecT function is necessary; also recombineering is more efficient 
when using ssDNA (Court et al., 2002 and Ellis et al., 2001).  This allowed for the 
convenience of using a synthetically made oligo as the substrate for recombination.  It 
YFG
transform 
into cells
ssDNA  oligo anneals to 
lagging strand allowing 
for homologous 
recombinationhomology
point mutation
YFG
Incorporation of point 
mutation into your 
favorite gene5’
5’
3’
3’
5 
 
 
has been demonstrated that recombineering is efficient in mycobacteria with as little as 
70bp of homology; however, to mutagenize large regions of genes, a series of 100bp 
oligos were used.   
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Chapter II Recombineering inhA and gyrA 
Introduction 
Isoniazid 
Isonicotinic acid hydrazide, also known as isoniazid (INH), was introduced in 1952 as the 
first effective treatment for tuberculosis, and it continues to be the primary first line drug 
against tuberculosis (Vilchèze and Jacobs, 2007).  The principal action of INH is against 
the mycobacterial cell wall by inhibiting the biosynthesis of mycolic acids, which results 
in a loss of acid-fastness and eventual cell lysis.  This inhibition is accomplished through 
interaction with the NADH dependent enoyl-acyl carrier protein reductase (InhA) of the 
fatty acid synthase II system.  Before interaction with InhA, INH needs to be activated by 
KatG (catalase-peroxidase-peroxynitritase).  KatG activation results in reaction with 
NADH thereby creating a NAD-INH adduct which binds to the InhA activation site 
(Wahab et al., 2009). 
 
Unfortunately, within the first year of its use, resistance to INH was identified in clinical 
isolates (Steenken et al., 1952).  INH resistance arises through several routes including 
mutations in: the inhA active site, the inhA 
upstream region/promoter, and within katG (Wang 
et al., 2011).  Approximately 22% of isolates, 
however, have no known resistance mechanism.  
Conversely, the mechanism of action for INH 
previously discussed was determined through study 
Table II.1 Commonly found mutations 
in inhA conferring resistance to INH 
from clinical and laboratory isolates. 
I16T= V78A$ 
I21T^ S94A~ 
I21V^ I95P$ 
I47T$ I194T^ 
Clinical isolates indicated in black text and 
laboratory isolates in gray text 
~Banerjee et al., 1994  
=Dessen etal., 1995  
$Basso et al., 1998  
^Ramaswamy et al., 2003 
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Figure II.1 M. tuberculosis InhA modeled with 
bound NADH.   
Region mutagenized for recombineering 
highlighted in yellow (PDB ID: 2AQ8). 
of mutations found in a relatively small number of clinical isolates.  Mutations within 
inhA decrease the affinity of the protein for the NAD-INH adduct via either structural 
changes that alter the architecture of active site or mutations within the active site itself 
(Oliveira et al, 2006).  Despite the active site spanning 42 amino acids and the NADH 
binding site spanning 185 amino acids there are only 8 known resistance-associated 
mutations within inhA (Table II.1).  This surprisingly low number in the mutations 
allowable to alter the InhA binding site led to the question: Are the reported clinical and 
laboratory mutations the only viable options for INH resistance arising from mutation in 
inhA or can novel mutations be isolated? 
 
Using the known amino acid sites for mutation and the amino acids within the InhA 
binding site, a 400bp region was selected 
for randomization via recombineering 
(Figure II.1 and Supplementary Table 1).  
As an initial study, these experiments were 
performed in Mycobacterium smegmatis 
(M. smegmatis), a non-pathogenic soil 
dwelling relative of M. tuberculosis 
commonly used in the laboratory due to its 
ease of use.  Therefore, it was necessary to 
determine the similarly between the 
sequences for inhA so the mutations could 
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be properly tracked.  The M. smegmatis inhA amino acid sequence is 94% identical to the 
M. tuberculosis sequence, with all the known mutations aligning properly 
(Supplementary Figure 2).  Therefore, it was determined M. smegmatis would be a 
suitable model. 
 
Fluoroquinolone 
The second line class of drugs known as fluoroquinolones is characterized by structural 
similarity to nalidixic acid and by the antimicrobial mode of action (Gorzynski et al., 
1989).  Fluoroquinolones target the type II topoisomerases, DNA gyrase and 
topoisomerase IV, of bacteria (Piton et al., 2010).  M. tuberculosis is unique in that it 
only encodes one of the two type II topoisomerases, the DNA gyrase.  Gyrase is an A2B2 
complex, and fluoroquinolones specifically target 
the subunit gyrase A (GyrA).  Fluoroquinolones 
bind the DNA-gyrase complex and stabilize the 
normally transient enzymatic reaction, thereby 
stalling DNA replication.  
 
The history of the fluoroquinolones is much more 
recent than that of INH with the introduction of the 
class as a treatment for TB in the early 1980s, and 
new compounds continue to be introduced into the 
drug market.  The continuing development of new 
Table II.2 Commonly found amino acid 
mutations in gyrA conferring resistance 
to FQ from clinical and laboratory 
isolates. 
T80A+ A90V~ 
A83V= S91P~ 
D87N= D94N~ 
D87A= D94A~ 
D87N= D94G~ 
G88C~ D94H~ 
G88C+ D94N~ 
G88A$ D94Y~ 
D89N^ S95T* 
D89G+ L96P* 
A90V~ D111N* 
Clinical isolates indicated in black text and 
laboratory isolates in gray text 
~Takiff et al., 1994 
=Alangaden et al., 1995 
$Matrat et al., 2006 
^VonGroll et al., 2009 
*Ali et al., 2011 
+Campbell et al., 2011 
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Figure II.2  Modeled mycobacterium GyrA. 
Region mutagenized for recombineering 
highlighted in yellow (PDB ID: 3IFZ). 
versions of fluoroquinolone as well as the 
rise in MDR and XDR-TB made including 
a fluoroquinolone in this study highly 
applicable.  The MIC90 values for the 
fluoroquinolones against M. tuberculosis 
range from 0.05mg/L to greater than 
8mg/L (Jacobs, 1999).  Ofloxacin (OFX), 
a commonly used antibiotic with a MIC90 
value of 0.2mg/L was the fluoroquinolone 
chosen for this work.  
 
Over 20 different mutations in gyrA, 
causing varying degrees of resistance to 
any of the fluoroquinolones, have been 
identified in either clinical or laboratory isolates (Table II.2).  All of these mutations fall 
in the region of gyrA that has been designated as the fluoroquinolone resistance 
determining region (QRDR), which extends from residue 74 to 113 in M. tuberculosis.  
The QRDR falls within the DNA-gate of GyrA and includes some of the most important 
residues for interaction with DNA.  Mutations within the QRDR decrease the affinity of 
the drug for the DNA-gyrase complex via disruption of the quinolone binding pocket 
(QBP) (Piton et al., 2010).  The QBP is the binding site for FQ made from residues 
within the QRDR as well as DNA.  Of the 30 amino acids that make up the QRDR only 
10 
 
 
11 mutations have been identified from either clinical or laboratory isolates.  Similar to 
inhA, this low number of mutations allowable for drug resistance led to the question: Are 
the reported clinical and laboratory mutations the only viable options for OFX resistance 
arising from mutation in gyrA or can novel mutations be isolated? 
 
Using the known amino acid sites for mutation and the amino acids within the QRDR a 
100bp region was chosen for randomization via recombineering (Figure II.2 and 
Supplementary Table 1).  Again, it was necessary to determine the similarly between the 
M. smegmatis and M. tuberculosis sequences for gyrA so the mutations could be properly 
tracked.  The M. smegmatis gyrA amino acid sequence is 95% identical to the M. 
tuberculosis sequence, with all the known mutations aligning properly (Supplementary 
Figure 3).  Therefore, it was determined M. smegmatis would be a suitable model. 
 
Materials and Methods 
Bacterial strains. Wild type M. smegmatis, mc2-155, competent cells were generated by 
growing in 7H9 media supplemented with 10% OADC and 1% Tween80 at 37°C while 
shaking to an OD of 1.0, spinning down the cultures at 4°C for 10min at 4000rpm, 
washing twice with 10% glycerol, and resuspending the culture in 10% glycerol at 1/10 
of the original culture volume.  Competent cells were frozen and stored at -80°C in 
400μL aliquots.  
Che9 RecT M. smegmatis strain pKM402 was designed and provided by Kenan 
Murphy.  The Che9 RecT expression plasmid, pKM402, was made as follows: RecT gene 
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generated by PCR from pJV53 with primers 655-
GTAGTACATATGGCTGAAAATGCTGTCACCAAG and 656- 
TTTCCCCCCCCCCCGACGTCAGGT cut with NdeI and NheI and ligated into 
pKM287 backbone (pKM287 is a derivative of pUV15tet-O).  Plasmid maps for 
pKM402 expression plasmid and pUV15tet-O can be seen in Supplemental Figure 1.   
pKM402 competent cells were generated by growing in 7H9 media supplemented 
with 10% OADC, 1% Tween80, and kanamycin (20μg/mL) at 37°C while shaking to an 
OD of 0.5 before inducing the expression of RecT with the addition of ATc50 and 
growing covered at 37°C while shaking to an OD of 1.0.  The cultures were then 
similarly spun down at 4°C for 10min at 4000rpm, washing twice with 10% glycerol, and 
resuspending the culture in 10% glycerol at 1/10 of the original culture volume.  Due to 
the decreased recombineering efficiency of frozen competent cells, pKM402 competent 
cells were always made fresh. 
Determination of MBC. The antibiotic concentration at which the bacteria are killed 
(MBC) was determined via plating.  Approximately 108 cells of mc2-155 were plated on 
individual plates containing either isoniazid (INH) or ofloxacin (OFX) at concentrations 
ranging from 0.1μg/mL – 100μg/mL for INH and from 0.01μg/mL – 100μg/mL for OFX.  
Plates were incubated for 3 days at 37°C and then checked for bacterial colonies.  The 
concentration at which no additional colonies above the background rate of spontaneous 
mutation were observed was used as the antibiotic concentration for low level resistant 
mutants (20μg/mL for INH and 0.5μg/mL for OFX).  High level resistant mutants were 
isolated using 30μg/mL for INH and 5.0μg/mL for OFX. 
12 
 
 
Custom oligos. Oligos were designed so that translated proteins would contain a single 
mutated amino acid within the region of interest.  This was accomplished by producing 
oligos that have mutations at every position within the region of interest at a probability 
of 1%.  For instance, at position 46 of inhA the wild type nucleotide is an adenine, and 
since the oligos are 100 bases in length, the oligo would be produced using a mixture of 
99% A, 0.33% C, 0.33% G, and 0.33% T.  However, since the company used (Integrated 
DNA Technologies) is unable to produce mixtures containing less than 1% of any given 
nucleotide the percentage was changed to 97% A, 1% C, 1% G, and 1% T. 
 Transformation. 0.5μg or 1.0μg of oligo DNA was added directly to competent cells 
before transferring the cell solution to a cuvette for electroporation.  Using the Bio-Rad 
Gene Pulser Xcell, the following settings were used for electroporation: 2500V, 25μF, 
and 1000Ω.  The electroporated cells were then transferred to 3mL 7H9 media 
supplemented with 10% OADC, and 1% Tween80 in round bottom tubes.  For outgrowth 
the tubes were placed at 37°C on a rotating wheel.  Per Kenan Murphy’s suggestion the 
usual outgrowth time for M. smegmatis after electroporation of 1 generation (3hrs) was 
extended to 4-6 generations (12-18 hrs) to allow for propagation of the mutation across 
all chromosomes.  The cultures were then spun down at 4°C for 10min at 4000rpm before 
resuspension in 7H9 media supplemented with 10% OADC, and 1% Tween80 for plating.  
Approximately 108 cells were plated on individual plates containing 20μg/mL INH, 
30μg/mL INH, 0.5μg/mL OFX, or 5.0μg/mL OFX.  Plates were incubated for 3 days at 
37°C and then checked for bacterial colonies.  
Primers. Primers were generated to flank the mutated regions of interest with at least 15 
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bases between the end of the primer and the adjoining region of interest for the purpose 
of sequencing.  The position of the primer in relation to the region of interest can be seen 
in Supplementary Table 1.  For sequencing and PCR of gyrA: gyrA_Fs-
ACGCGATGTACGACTCGGCT; gyrA_Rs-AAGTTGCCCTGGCCGTCCACCA.  For 
sequencing and PCR of inhA: inhA_F-ATGACAGGCCTACTCGAAGG; inhA_R-
GCGTCGGGTCCTTCATGTTC.  Also used were a set of positive control primers, 
S1109 and S1116, given by Kadamba Papavinasasundaram that is known to amplify the 
region of M. smegmatis DNA going across the pknA-pknB junction.  This gene 
organization exists in other mycobacteria, but in other organisms the primers do not bind 
with high specificity under the conditions used.  
PCR. Following incubation of the transformed cells on selection media colonies were 
picked.  The picked colonies were transferred to 3mL 7H9 media supplemented with 10% 
OADC, and 1% Tween80 in round bottom tubes and placed at 37°C on a rotating wheel 
for 3 days.  Before sequencing, the cultures were checked for the presence of inhA and 
gyrA using PCR.  The PCR conditions used were those established to be specific for the 
positive control primers, S1109 and S1116: initial denaturation for 3 minutes at 96°C 
followed by for 30 cycles, denaturation for 30 seconds at 96°C, annealing for 30 seconds 
at 60°C, and extension for 1 minute 30 seconds at 72°C. 
Sequencing.  Purified PCR products were submitted to GENEWIZ, Inc. for sequencing 
using the primers indicated above.  The isolate sequences were aligned to the wild type 
mc2-155 sequence for either inhA or gyrA to identify mutations. 
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Results 
Increase in survivors following transformation with oligo.  Following transformation 
of pKM402 M. smegmatis cells and subsequent incubation, the frequency of drug 
resistant mutants was determined.  Cells transformed with the mutated inhA oligo gave 
rise to approximately twice as many survivor colonies when plated on 20μg/mL INH than 
mock transformed cells (Figure II.3A).   Similarly, cells transformed with the mutated 
gyrA oligo show a two fold increase in survivor colonies when plated on 0.5μg/mL OFX 
(Figure II.3C).  To approximate the frequency of mutation for transformed cells the 
amount of colonies present on plates was divided by the amount of cells plated (Figure 
II.3B and Figure II.3D).      
 
A size restriction was applied when the colonies on INH were counted because of the 
great difference in the size of the survivor colonies.  The control colonies on INH showed 
two distinctive sizes, either pinprick sized colonies or normal sized colonies.  The 
transformed colonies, on the other hand, showed a range of colony sizes from pinprick to 
large.  The pinprick sized colonies were considered as non-resistant and were not 
included in the adjusted values shown.  
 
PCR of isolates shows presence of inhA and gyrA.  Following growth of picked 
survivor colonies in broth, the cultures were used for PCR to test for the presence of 
either inhA or gyrA.  PCR products run on an agarose gel confirmed the presence of the 
indicated genes (Figure II.4).  
15 
 
 
 
 
pKM402 gyrAa
pKM402 Control
pKM402 gyrAb
C D
pKM402 inhA1b pKM402 inhA2b
pKM402 inhA3b
pKM402 Control
pKM402 inhA4b
A B
Figure II.3 Transformation with the mutated inhA oligo increases the frequency of resistance to 
20μg/mL INH and transformation with the mutated gyrA oligo increases the frequency of 
resistance to 0.5μg/mL OFX.  
A Example of colony counts. B Frequency of spontaneous mutation for mc2-155 and pKM402 on 
20μg/mL OFX compared to the frequency of mutation of pKM402 with inhA oligo. For mc2-155 n=9, 
pKM402 n=7 and pKM402 inhA n=8. Using unpaired t test, *p value<0.05, **p value<0.01 C Example 
of colony counts. D Frequency of spontaneous mutation for mc2-155 and pKM402 on 0.5μg/mL OFX 
compared to the frequency of mutation of pKM402 with gyrA oligo. For mc2-155 n=5, pKM402 n=4 
and pKM402 gyrA n=2. Using unpaired t test, *p value<0.0005, **p value<0.0001 
16 
 
 
 
Figure II.4 PCR check for pKM402 inhA and pKM402 gyrA survivors.   
A Cells transformed with 0.5μg inhA oligo DNA.  B Cells transformed with 1.0μg inhA oligo DNA.  C 
Cells transformed with either 1.0μg or 0.5μg gyrA oligo DNA. Controls were performed using wild type 
mc2-155 and the RecT  pKM402 strains; (+) primers targeting a 1.26kb segment present only in the 
mycobacterial genome, (-) no primers added, (i) primers targeting inhA, and (g) primers targeting gyrA. 
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Figure II.5 Number of mutations per gene for 
inhA and gyrA isolates, excluding silent 
mutations.   
In total, 54 inhA and 10 gyrA isolates were 
sequenced. 
 
Sequencing of isolates shows no novel 
mutations.  PCR products were 
sequenced to determine if any mutations 
in the region mutagenized were present.  
The percentage of isolates containing 
mutations in the region sequenced was 
high; 48/64 (75%) isolates contained 
mutations.  Of the isolates with mutations, 
8/48 contained two mutations per gene, and of those, 4 had a silent mutation as the 
second mutation (Figure II.5).    
 
Four novel mutations were determined within the region of inhA mutated and no novel 
mutations were determined within the region of gyrA mutated (Table II.3).  This is 
evident by comparing the survivor mutations with the established laboratory derived and 
clinical isolates discussed earlier (Table II.1 and Table II.2).  However, the novel 
mutations in inhA were paired with currently established isolate mutations.  Only one 
mutation was determined to be outside of the regions mutated, and was present in an 
isolate with inhA mutated (Supplementary Table 5).  This isolate, though, contained a 
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currently established isolate mutation, and is thus considered as one of the naturally 
occurring spontaneous mutants. 
 
Discussion 
The aim of this work was to explore the ability of recombineering based mutagenesis to 
determine drug resistance.  The first major conclusion was that novel mutations in INH 
resistant isolates were only identified as second site mutations.  These “novel” mutations 
were paired with mutations previously established to confer resistance in either clinical or 
laboratory isolates, therefore the role these second site mutations play in the overall 
resistance has yet to be determined.  Of the four “novel” mutations N86T is thought to be 
the only insignificant change because the amino acid change is a conservative 
substitution.  The other three mutations (E31K, G83D, and Y182L) are thought to cause 
 
Table II.3 Mutations in inhA and gyrA determined following sequencing of survivors.  
Survivor Mutation 
Established Isolate 
Incidences 
Laboratory Clinical 
inhA 
I21N - I21T, V 7 
I21N, E31K - I21T, V 1 
I21T - I21T, V 2 
I47A* - I47T 1 
S94A S94A - 10 
S94A, G83D S94A - 1 
S94A, N86T S94A - 1 
I194N - I194T 6 
I194S - I194T 7 
I194S, Y182L* - I194T 1 
     
gyrA 
D95A D94N+ D94A, G, H, N, Y 2 
D95N D94N D94A, G, H, N, Y 4 
D95Y D94N D94A, G, H, N, Y 4 
*Mutation reported is the amino acid present in M. tuberculosis. 
+There is an accepted inconsistency in the numbering system for gyrA (Maruri et al., 2012). 
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possible structural changes in the InhA 
active site (Figure II.6).  The E31K 
mutation is at the C-terminal end of the 
α1 helix, which at the N-terminal end is a 
part of the active site.  Therefore, it is 
thought the positioning of the α1 helix 
could be altered, disrupting the active 
site interactions.  The G83D mutation is 
just downstream of the clinical mutation 
V78A, in the α3 helix.  Unfortunately, the 
role the V78A mutation plays in 
resistance has not been explored, but the N-terminal end of the α3 helix is a part of the 
active site.  Therefore, again it is thought the positioning of the α3 helix could be altered, 
disrupting the active site interactions.  The Y182L mutation is in an unusual position 
within the protein, the α5β6 linker, providing the potential for alteration of either the α5 
helix and/or the β6 sheet, which both have residues in the active site.  As a future 
experiment, the importance of these mutations could be determined by creating single 
mutants, and testing for INH resistance. 
 
Another major development from this work is that mutations previously determined only 
in clinical isolates are viable laboratory isolates.  In inhA only one laboratory isolate 
mutation was previously determined, S94A, so the viability of other mutations in vitro 
Figure II.6 M. tuberculosis InhA modeled with 
bound NADH and mutated residues found in 
survivors.   
All eight mutated residues (I21, E31, I47, G83, 
N86, S94, Y182 and I194) are shown in yellow. 
I21
I47
S94
E31
I194
Y182
N86
G83
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was in question.  This work did find that mutations in I21, I47, and I194 are all viable in 
vitro.  Why no mutations other than S94A have been found in laboratory isolates could be 
the result of no other experiments having been reported since the 1994 Banerjee et al 
study. 
 
Finally, it was determined that amino acid residues previously determined in clinical 
isolates have more variability, in other words, novel substitutions were determined.  For 
instance, residue 47 is commonly found mutated from Ile to Thr in clinical isolates, but in 
this work the mutation found was I47A.  Similar mutational differences were found for 
I21 and I194.  These mutations were found to generate viable bacteria in vitro; however, 
these mutants may not be viable in vivo which could explain their absence in clinical 
isolates.  The viability of these mutants in vivo could be tested in mice.  
 
The experiment performed with gyrA demonstrated the inflexibility of FQ conferring 
mutations.  Of the 10 isolates sequenced all 10 were at the same residue, and all 10 were 
previously established amino acid changes from either clinical or laboratory isolates.  
However, only 10 isolates were sequenced, and it has been determined up to 90% of all 
FQ resistant isolates have mutations in either D94 or A90 (Zhang and Telenti 2000).  
With continued work it is possible other mutations within the QRDR could be found.    
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Appendix 
 
 
 
 
 
 
Figure A1. Plasmid design for pKM402 (Che9 RecT expression plasmid).   
The pKM402 plasmid was made as follows: Generated RecT gene by PCR from pJV53 with primers 655 
and 656. Cut with NdeI and NheI and ligated into pKM287 backbone (pKM287 is a derivative of 
pUV15tet-O).  
Primer 655 RecT-NdeI GTAGTACATATGGCTGAAAATGCTGTCACCAAG 
Primer 656 RecT-NheI TTTCCCCCCCCCCCGACGTCAGGT (NheI site is in the vector) 
 
 
  
-10 289...294
tetO 272...288
-35 266...271
tetO 247...263
rrnB2 23...42
tetR 5669...6291
ptb21(int) 5502...5639
rrnBT2 5463...5480
cat gene 6424...7083
oriE 7296...7828
pKM402
8069 bp
Ptet promoter 72...377
RecT 406...1467
terminator 1504...1594
Kan 1739...2554
T4g32 term 2584...2613
oriM 2676...5150
pUV15tetO
8026 bp
rrnBT2 4903...4920
ptb21(int) 4942...5079
tetR 5109...5731
T4g32 5767...5785
hygR 6836...5839
oriE 7253...7785
rrnB2 23...42
UV15tetO 72...377
GFP 406...1122
kan 1144...1994
T4g32 2023...2040
oriM 2116...4590
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Score = 491 bits (1265), Expect = 6e-176, Identities = 235/269 (87%), Positives = 254/269 
(94%), Gaps = 0/269 (0%) 
M sm.  1   MTGLLEGKRILVTGIITDSSIAFHIAKVAQEAGAELVLTGFDRLKLVKRIADRLPKPAPLLELDVQNEEH 70 
           MTGLL+GKRILV+GIITDSSIAFHIA+VAQE GA+LVLTGFDRL+L++RI DRLP  APLLELDVQNEEH 
M tb.  1   MTGLLDGKRILVSGIITDSSIAFHIARVAQEQGAQLVLTGFDRLRLIQRITDRLPAKAPLLELDVQNEEH 70 
 
M sm.  71  LSTLADRITAEIGEGNKIDGVVHSIGFMPQSGMGINPFFDAPYEDVSKGIHISAYSYASLAKAVLPIMNP 140 
           L++LA R+T  IG GNK+DGVVHSIGFMPQ+GMGINPFFDAPY DVSKGIHISAYSYAS+AKA+LPIMNP 
M tb.  71  LASLAGRVTEAIGAGNKLDGVVHSIGFMPQTGMGINPFFDAPYADVSKGIHISAYSYASMAKALLPIMNP 140 
 
M sm.  141 GGGIVGMDFDPTRAMPAYNWMTVAKSALESVNRFVAREAGKVGVRSNLVAAGPIRTLAMSAIVGGALGDE 210 
           GG IVGMDFDP+RAMPAYNWMTVAKSALESVNRFVAREAGK GVRSNLVAAGPIRTLAMSAIVGGALG+E 
M tb.  141 GGSIVGMDFDPSRAMPAYNWMTVAKSALESVNRFVAREAGKYGVRSNLVAAGPIRTLAMSAIVGGALGEE 210 
 
M sm.  211 AGQQMQLLEEGWDQRAPLGWNMKDPTPVAKTVCALLSDWLPATTGTVIYADGGASTQLL 269 
           AG Q+QLLEEGWDQRAP+GWNMKD TPVAKTVCALLSDWLPATTG +IYADGGA TQLL 
M tb.  211 AGAQIQLLEEGWDQRAPIGWNMKDATPVAKTVCALLSDWLPATTGDIIYADGGAHTQLL 269 
 
Figure A2. Sequence alignment (protein BLAST) between Mycobacterium smegmatis inhA and 
Mycobacterium tuberculosis inhA. 
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Score = 1535 bits (3975), Expect = 0.0, Identities = 753/835 (90%), Positives = 797/835 
(95%), Gaps = 1/835 (0%) 
M sm.  1   MTDTTLPPEGEAHDRIEPVDIQQEMQRSYIDYAMSVIVGRALPEVRDGLKPVHRRVLYAMYDSGFRPDRS 70 
           MTDTTLPP+ ++ DRIEPVDI+QEMQRSYIDYAMSVIVGRALPEVRDGLKPVHRRVLYAM+DSGFRPDRS 
M tb.  1   MTDTTLPPD-DSLDRIEPVDIEQEMQRSYIDYAMSVIVGRALPEVRDGLKPVHRRVLYAMFDSGFRPDRS 69 
 
M sm.  71  HAKSARSVAETMGNYHPHGDASIYDTLVRMAQPWSLRYPLVDGQGNFGSPGNDPPAAMRYTEARLTPLAM 140 
           HAKSARSVAETMGNYHPHGDASIYD+LVRMAQPWSLRYPLVDGQGNFGSPGNDPPAAMRYTEARLTPLAM 
M tb.  70  HAKSARSVAETMGNYHPHGDASIYDSLVRMAQPWSLRYPLVDGQGNFGSPGNDPPAAMRYTEARLTPLAM 139 
 
M sm.  141 EMLREIDEETVDFIPNYDGRVQEPTVLPSRFPNLLANGSGGIAVGMATNIPPHNLGELAEAVYWCLENYE 210 
           EMLREIDEETVDFIPNYDGRVQEPTVLPSRFPNLLANGSGGIAVGMATNIPPHNL ELA+AV+W LEN++ 
M tb.  140 EMLREIDEETVDFIPNYDGRVQEPTVLPSRFPNLLANGSGGIAVGMATNIPPHNLRELADAVFWALENHD 209 
 
M sm.  211 ADEEATCEAVMERVKGPDFPTSGLIVGTQGIEDTYKTGRGSIKMRGVVEIEEDSRGRTSIVITELPYQVN 280 
           ADEE T  AVM RVKGPDFPT+GLIVG+QG  D YKTGRGSI+MRGVVE+EEDSRGRTS+VITELPYQVN 
M tb.  210 ADEEETLAAVMGRVKGPDFPTAGLIVGSQGTADAYKTGRGSIRMRGVVEVEEDSRGRTSLVITELPYQVN 279 
 
M sm.  241 HDNFITSIAEQVRDGKLAGISNIEDQSSDRVGLRIVVELKRDAVAKVVLNNLYKHTQLQTSFGANMLSIV 350 
           HDNFITSIAEQVRDGKLAGISNIEDQSSDRVGLRIV+E+KRDAVAKVV+NNLYKHTQLQTSFGANML+IV 
M tb.  240 HDNFITSIAEQVRDGKLAGISNIEDQSSDRVGLRIVIEIKRDAVAKVVINNLYKHTQLQTSFGANMLAIV 349 
 
M sm.  351 DGVPRTLRLDQLIRLYVDHQLDVIVRRTRYRLRKANERAHILRGLVKALDALDEVIALIRASQTVDIARA 420 
           DGVPRTLRLDQLIR YVDHQLDVIVRRT YRLRKANERAHILRGLVKALDALDEVIALIRAS+TVDIARA 
M tb.  350 DGVPRTLRLDQLIRYYVDHQLDVIVRRTTYRLRKANERAHILRGLVKALDALDEVIALIRASETVDIARA 419 
 
M sm.  421 GLIELLDIDDIQAQAILDMQLRRLAALERQKIVDDLAKIEAEIADLEDILAKPERQRGIVRDELKEIVDK 490 
           GLIELLDID+IQAQAILDMQLRRLAALERQ+I+DDLAKIEAEIADLEDILAKPERQRGIVRDEL EIVD+ 
M tb.  420 GLIELLDIDEIQAQAILDMQLRRLAALERQRIIDDLAKIEAEIADLEDILAKPERQRGIVRDELAEIVDR 489 
 
M sm.  491 HGDARRTRIVPADGEVSDEDLIAREDVVVTITETGYAKRTKTDLYRSQKRGGKGVQGAGLKQDDMVNHFF 560 
           HGD RRTRI+ ADG+VSDEDLIAREDVVVTITETGYAKRTKTDLYRSQKRGGKGVQGAGLKQDD+V HFF 
M tb.  490 HGDDRRTRIIAADGDVSDEDLIAREDVVVTITETGYAKRTKTDLYRSQKRGGKGVQGAGLKQDDIVAHFF 559 
 
M sm.  561 VCSTHDWILFFTTQGRVYRAKAYELPEASRTARGQHVANLLAFQPEERIAQVIQIKSYEDAPYLVLATRN 630 
           VCSTHD ILFFTTQGRVYRAKAY+LPEASRTARGQHVANLLAFQPEERIAQVIQI+ Y DAPYLVLATRN 
M tb.  560 VCSTHDLILFFTTQGRVYRAKAYDLPEASRTARGQHVANLLAFQPEERIAQVIQIRGYTDAPYLVLATRN 529 
 
M sm.  601 GLVKKSKLSDFDSNRSGGIVAINLREGDELVGAVLCSAEDDLLLVSANGQSIRFSATDEALRPMGRATSG 700 
           GLVKKSKL+DFDSNRSGGIVA+NLR+ DELVGAVLCSA DDLLLVSANGQSIRFSATDEALRPMGRATSG 
M tb.  600 GLVKKSKLTDFDSNRSGGIVAVNLRDNDELVGAVLCSAGDDLLLVSANGQSIRFSATDEALRPMGRATSG 699 
 
M sm.  701 VQGMRFNEDDRLLSLNVVRPDTYLLVATSGGYAKRTSIDEYSVQGRGGKGILTIQYDRKRGSLVGALIVD 770 
           VQGMRFN DDRLLSLNVVR  TYLLVATSGGYAKRT+I+EY VQGRGGKG+LT+ YDR+RG LVGALIVD  
M tb.  700 VQGMRFNIDDRLLSLNVVREGTYLLVATSGGYAKRTAIEEYPVQGRGGKGVLTVMYDRRRGRLVGALIVD 769 
 
M sm.  721 DDTELYAITSTGGVIRTAARQVRKAGRQTKGVRLMNLAEGDTLIAIARNADEDEAAESISESDAD 835 
           DD+ELYA+TS GGVIRTAARQVRKAGRQTKGVRLMNL EGDTL+AIARNA+E     ++  + AD 
M tb.  720 DDSELYAVTSGGGVIRTAARQVRKAGRQTKGVRLMNLGEGDTLLAIARNAEESGDDNAVDANGAD 834 
 
Figure A3. Sequence alignment (protein BLAST) between Mycobacterium smegmatis gyrA and 
Mycobacterium tuberculosis gyrA. 
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Table A1. Mycobacterium smegmatis wild type sequences for inhA and gyrA. 
Gene Sequence (5'3') 
inhA ATGACAGGCC TACTCGAAGG caagcgcatc ctcgtcacgg ggatcATCAC CGATTCGTCG ATCGCGTTCC 
ACATCGCCAA GGTCGCCCAG GAGGCCGGCG CCGAACTGGT GCTGACCGGT TTCGACCGCC TGAAGTTGGT 
CAAGCGCATC GCCGACCGCC TGCCCAAGCC GGCCCCGCTG CTGGAACTCG ACGTGCAGAA Cgaggagcac 
ctgtcgactc tggccgaccg gATCACCGCC GAGATCGGTG AGGGCAACAA GATCGACGGT GTGGTGCACT 
CGATCGGGTT CATGCCGCAG AGCGGTATGg gcatcaaccc gttcttcgac gcgccgtacg aggatgtgtc 
caagggcatc cacatctcgg cgtactcgta cgcctcgctc gccaaagccg ttctgccgat catgaatccg 
ggcggcggca tcgtcggcat ggacttcgac cccacgcgcg cgatgccggc ctacaactgg atgaccgtcg 
ccaagagcgc gctcgaatcg GTCAACCGGT TCGTCGCGCG TGAGGCGGGC AAGGTGGGCG TGCGCTCGAA 
TCTCGTTGCG GCAGGACCGA TCCGCACGct ggcgatgagc gcaatcgtgg gcggtgcgct gggcgacgag 
gccggccagc agatgcagct gctcgaagag ggctgggatc agcgcgcgcc gctgggctgG AACATGAAGG 
ACCCGACGCc cgtcgccaag accgtgtgcg cactgctgtc ggactggctg ccggccacca ccggcaccgt 
gatctacgcc gacggcggcg ccagcacgca gctgttgtga t 
  
gyrA atgactgata cgacgctgcc gccggaaggc gaggcgcatg accggatcga accggtcgac atccagcagg 
agatgcagcg cagctacatc gactacgcca tgagcgtgat cgtgggccgc gcgctgcccg aggtgcgcga 
cggtctcaag cccgtgcacc gccgcgtgct gtACGCGATG TACGACTCGG CTtcgtcgga tcgcagccac 
gccaaatccg cgcgctccGT TGCCGAGACG ATGGGTAACT ACCATCCGCA CGGCGACGCC TCGATCTACG 
ACACCCTGGT CCGCATGGCC CAGCCGtggt cgttgcgcta cccgcTGGTG GACGGCCAGG GCAACTTcgg 
ctcgccgggt aacgatccgc cagcggccat gcgttacacc gaagcgcgac tcactccgtt ggcgatggag 
atgttgcgtg aaatcgacga ggagacagtc gatttcatcc cgaactacga cggacgggtg caggagccca 
cggttctgcc gagccggttt cccaacctgt tggccaacgg ttcgcgcggt atcgccgtgg gcatggccac 
caacaacccg ccgcacaacc tcggcgagct cgcggaggcc gtgtactggt gcctggagaa ttacgaggcc 
gacgaggaag ccacctgcga ggccgtgatg gagcgggtca agggacccga cttccccacg tccggcctga 
tcgtgggcac ccagggtatc gaggacacgt acaagaccgg ccgcgggtcg atcaagatgc gtggcgtcgt 
cgagatcgag gaggacagcc ggggacggac cagcatcgtc atcaccgagc tgccctacca ggtcaaccac 
gacaacttca tcacctcgat cgccgagcag gtgcgcgacg gcaagctcgc gggcatctca aacatcgagg 
accagtccag tgaccgtgtg ggcctgcgaa ttgtcgtgga gctcaagcgc gatgcggtcg ccaaggtggt 
gctgaacaac ctctacaagc acacccagct gcagaccagc ttcggcgcca acatgctgtc gatcgtcgac 
ggtgtgccgc gcacgctgcg cctggaccag ctgatccgcc tgtacgtcga ccaccaactc gatgtcatcg 
tgcggcgcac ccggtaccgg ctgcgcaagg ccaacgaacg ggcccacatc ctgcgtggtc tggtcaaggc 
actcgatgcc ctcgacgagg tcatcgcgtt gatccgggcg tcgcagaccg tcgacatcgc gcgtgccggc 
ctgatcgagc tgctcgacat cgacgacatc caggcccagg cgatcctcga catgcagctg cgcaggctcg 
cagccctcga gcggcagaag atcgtcgacg acctcgccaa gatcgaggcc gagatcgccg acctcgagga 
catcctcgcc aagcccgagc ggcagcgcgg gatcgtgcgt gacgagctca aggagatcgt cgacaagcac 
ggcgacgcgc gtcggacccg catcgtgccc gccgacgggc aggtcagcga cgaggatctc atcgcccgcg 
aagacgtggt ggtcaccatc accgagaccg gctacgccaa acgcaccaag accgacctgt accacagcca 
gaaacgcggc ggcaaaggtg tgcagggtgc cggcctcaag caggacgaca tggtcaacca cttcttcgtc 
tgctcgacgc acgactggat cctgttcttc accacacagg gtcgcgtgta ccgggcgaag gcgtacgagt 
tgcccgaggc gtcccgcacc gcgcgtggcc agcacgtcgc gaacctcctg gccttccagc ccgaggagcg 
catcgcgcag gtcatccaga tcaagagcta cgaggatgcg ccctacctgg tgctcgcgac ccgcaatggt 
ctggtgaaga agtccaagct gtccgacttc gactccaacc gctccggcgg catcgtcgcg atcaacctgc 
gggaaggcga cgaactggtc ggtgcggtgc tgtgctcggc agaggacgac ctgctcctgg tgagtgccaa 
ccgccagtcg atccgcttct cggcgaccga cgaggcgctg cggcccatgg gtcgcgccac ctccggtgtg 
cagggcatgc ggttcaacga ggacgaccgc ctgctgtcgc tcaacgtcgt ccggcccgat acgtatctgc 
tggtcgcgac atcgggtggc tacgccaagc gcacctcgat cgacgagtac tcggtgcagg gccgcggcgg 
caagggcatc ctgacgatcc agtacgaccg caaacgtggc agtctggtcg gagcgttgat cgtcgacgac 
gacaccgagc tgtacgcgat cacgtccaca ggtggtgtca tccgcactgc cgcacgtcag gtccgcaagg 
ctggtcgcca gacaaagggc gttcgcttga tgaacctggc cgagggcgac acactgattg ccatcgcccg 
caacggacga ggacgaggcg gccgagtcga tcagcgaatc cgacgcggac accgccgagt cacccgaggc 
gtgatggaaa cgctgaggtc ccgaaaggtc ctcggcccga gctaaggagc tgtaggtgag ttcacccaac 
gagccgggat acccgcgcgc gggggaccgg ccgggcgcca ccaacggcac gggtccgggc ggcgacagcg 
gagccctcag cagcaactcg acgcgggcca cggggcacat caccgattcc ggtgacgtgc ccccgtggca 
gcgcggggtc tcccgcaccg ctcagcaacc tggtcagccg ctcggcgaca ccgagcagca gccccgtccc 
gcgccgaggc ccgagccccg cgagacccgc caggagccgc ggcctgaaca tcgcaccgag gcctacgcga 
gcgagttgcc ggacctctcg ggtccggtcc cccgctcacc gcagcgcaag accggggccg acgcgccccg gg 
PRIMER FOR SEQUENCING 
area of interest to mutate 
INHA1 OLIGO 
INHA2 OLIGO 
INHA3 OLIGO 
INHA4 OLIGO 
GYRA OLIGO 
unmutated regions 
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Table A2. Oligos designed for this work. 
Wild type oligos manufactured by Sigma-Aldrich.  Mutant oligos manufactured by IDT and indicated by a 
2 digit percentage.  For instance, at a particular position a mixture of 97% A, 1% C, 1% G, and 1% T is 
denoted by 97010101.  1=97010101, 2=01970101, 3=01019701, 4=01010197 
Name Sequence (5’3’) 
GyrA_Mt CCGCGCGCTCC34T32C31312G14333T11241221422G21233C31232C42G14241231
212C24G34C23C14332C21322GTGGTCGTTGCG 
GyrA_WT 
 
CCGCGCGCTCCGTTGCCGAGACGATGGGTAACTACCATCCGCACGGCGACGC
CTCGATCTACGACACCCTGGTCCGCATGGCCCAGCCGTGGTCGTTGCG 
InhA1_Mt  
 
TCACGGGGATC14212C31442342314232G44221214232C11334C32C21331332C33
C32C31124G34G24G12C33T442GACCGCCTGAA 
InhA1_WT 
 
TCACGGGGATCATCACCGATTCGTCGATCGCGTTCCACATCGCCAAGGTCGC
CCAGGAGGCCGGCGCCGAACTGGTGCTGACCGGTTTCGACCGCCTGAA 
InhA2_Mt 
 
TGACCGGTTTC31223C24G11344334C11323C14232C31223C24G22C11322G32C22
G24G24G31124C31234G213112GAGGAGCACCT 
InhA2_WT 
 
TGACCGGTTTCGACCGCCTGAAGTTGGTCAAGCGCATCGCCGACCGCCTGCC
CAAGCCGGCCCCGCTGCTGGAACTCGACGTGCAGAACGAGGAGCACCT 
InhA3_Mt 
 
TGGCCGACCGG14212C32C31314233T31333C11211314231233T34G34G21242G14
2333T4214322G21313233T143GGCATCAACCC 
InhA3_WT 
 
TGGCCGACCGGATCACCGCCGAGATCGGTGAGGGCAACAAGATCGACGGTG
TGGTGCACTCGATCGGGTTCATGCCGCAGAGCGGTATGGGCATCAACCC 
InhA4_Mt 
 
CGCTCGAATCG34C11223344234C32G23T31332G33C11334G33C34G23C42G1142
4C34T32G32A33A22G14223C12GCTGGCGATGAG 
InhA4_WT 
 
CGCTCGAATCGGTCAACCGGTTCGTCGCGCGTGAGGCGGGCAAGGTGGGCG
TGCGCTCGAATCTCGTTGCGGCAGGACCGATCCGCACGCTGGCGATGAG 
 
 
Table A3. Primers designed for this work. 
Purpose Name Sequence (5'3') 
For sequencing and PCR of gyrA 
gyrA-Fs 173-ACGCGATGTACGACTCGGCT-193  
gyrA-Rs 326-AAGTTGCCCTGGCCGTCCACCA-348   
   
For sequencing and PCR of inhA 
inhA-F 001-ATGACAGGCCTACTCGAAGG-021 
inhA-R  690-GCGTCGGGTCCTTCATGTTC-710 
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Table A4. Results of sequencing of pKM402 inhA survivor isolates 
Survivor 
Isolate 
Survivor Mutation  Established  Isolate 
Nucleotide Amino Acid  Laboratory Clinical 
inhA1-1 
61-atc 
I21T 
  
- I21T, V 
61-acc  
inhA1-2 
61-atc 
I21N 
 
- I21T, V 
61-aac  
inhA1-3 - NM 
 
- - 
 
inhA1-4 - NM 
 
- - 
 
inhA1-5 
55-tcg 
S19S 
 
- - 
55-tca  
61-atc 
I21T 
 
- I21T, V 
61-acc  
inhA1-6 - NM 
 
- - 
 
inhA1-7 
61-atc 
I21N 
 
- I21T, V 
61-aac  
inhA1-8 - NS 
 
- - 
 
inhA1-9 - NS 
 
- - 
 
inhA1-10 - NS 
 
- - 
 
inhA2-1 
139-att 
I47A* 
  
- I47T 
139-gcc  
inhA2-2 - NM 
 
- - 
 
inhA2-3 - NM 
 
- - 
 
inhA2-4 - NM 
 
- - 
 
inhA2-5 - NM 
 
- - 
 
inhA2-6 - NM 
 
- - 
 
inhA2-7 - NM 
 
- - 
 
inhA2-8 - NS 
 
- - 
 
inhA2-9 - NS 
 
- - 
 
inhA2-10 - NS 
 
- - 
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Table A4 continued. Results of sequencing of pKM402 inhA survivor isolates 
Survivor 
Isolate 
Survivor Mutation  Established Isolate 
Nucleotide Amino Acid   Laboratory Clinical 
InhA3-1 - NM 
 
- - 
 
InhA3-2 
280-tcg 
S94A 
 
S94A - 
280-gcg  
InhA3-3 
280-tcg 
S94A 
 
S94A - 
280-gcg  
InhA3-4 - NM 
 
- - 
 
InhA3-5 
280-tcg 
S94A 
 
S94A - 
280-gcg  
InhA3-6 
280-tcg 
S94A 
 
S94A - 
280-gcg  
InhA3-7 
280-tcg 
S94A 
 
S94A - 
280-gcg  
580-atc 
I95I 
 
- - 
580-agc  
InhA3-8 - NS 
 
- - 
 
InhA3-9 - NS 
 
- - 
 
InhA3-10 - NS 
 
- - 
  
InhA4-1 
580-atc 
I194S 
 
- I194T 
580-agc  
InhA4-2 
544-tac 
 Y182L* 
 
- - 
544-ttg  
580-atc 
I194S 
 
- I194T 
580-agc  
InhA4-3 
580-atc 
I194N 
 
- I194T 
580-aac  
InhA4-4 
580-atc 
I194N 
 
- I194T 
580-aac  
InhA4-5 
580-atc 
I194N 
 
- I194T 
580-aac  
InhA4-6 
580-atc 
I194S 
 
- I194T 
580-agc  
InhA4-7 
580-atc 
I194N 
 
- I194T 
580-aac  
InhA4-8 - NS 
 
- - 
 
InhA4-9 - NS 
 
- - 
 
InhA4-10 - NS 
 
- - 
  
*Mutation reported is the amino acid present in M. tuberculosis 
Silent mutations indicated in gray text; NS, not sequenced; NM, no mutation 
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Table A5. Results of sequencing of pKM402 inhAb survivor isolates. 
Survivor 
Isolate 
Survivor Mutation  Established  Isolate 
Nucleotide Amino Acid   Laboratory Clinical 
inhA1-1b 
61-atc 
I21N 
  
- I21T, V 
61-aac  
inhA1-2b 
61-atc 
I21N 
 
- I21T, V 
61-aac  
91-gag 
E31K 
 
- - 
91-aag  
inhA1-3b 
61-atc 
I21N 
 
- I21T, V 
61-aac  
inhA1-4b 
61-atc 
I21N 
 
- I21T, V 
61-aac  
inhA1-5b 
61-atc 
I21N 
 
- I21T, V 
61-aac  
inhA1-6b 
61-atc 
I21N 
 
- I21T, V 
61-aac  
inhA1-7b - NS 
 
- - 
 
inhA1-8b - NS 
 
- - 
 
inhA1-9b - NS 
 
- - 
 
inhA1-10b - NS 
 
- - 
  
inhA2-1b 
580-atc 
I194N 
 
- I194T 
580-aac  
inhA2-2b - NM 
 
- - 
 
inhA2-3b - NM 
 
- - 
 
inhA2-4b - NM 
 
- - 
 
inhA2-5b - NM 
 
- - 
 
inhA2-6b - NM 
 
- - 
  
inhA3-1b - NS 
 
- - 
 
inhA3-2b - NS 
 
- - 
 
inhA3-3b - NS 
 
- - 
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Table A5 continued. Results of sequencing of pKM402 inhAb survivor isolates. 
Survivor 
Isolate 
Survivor Mutation  Established  Isolate 
Nucleotide Amino Acid   Laboratory Clinical 
inhA3-4b 
280-tcg 
S94A 
 
S94A - 
280-gcg  
inhA3-5b 
257-aac 
N86T 
 
- - 
257-acc  
280-tcg 
S94A 
 
S94A - 
280-gcg  
inhA3-6b 
280-tcg 
S94A 
 
S94A - 
280-gcg  
inhA3-7b 
280-tcg 
S94A 
 
S94A - 
280-gcg  
inhA3-8b 
247-ggg 
G83D* 
 
- - 
247-gat  
280-tcg 
S94A 
 
S94A - 
280-gcg  
inhA3-9b 
280-tcg 
S94A 
 
S94A - 
280-gcg  
285-ggg 
G96G 
 
- - 
285-ggt  
inhA3-10b 
280-tcg 
S94A 
 
S94A - 
280-gcg   
inhA4-1b 
580-atc 
I194S 
 
- I194T 
580-agc  
inhA4-2b 
580-atc 
I194N 
 
- I194T 
580-aac  
inhA4-3b 
580-atc 
I194S 
 
- I194T 
580-agc  
inhA4-4b 
532-gag 
E178E 
 
- - 
532-gaa  
580-atc 
I194S 
 
- I194T 
580-agc  
inhA4-5b 
580-atc 
I194S 
 
- I194T 
580-agc  
inhA4-6b 
580-atc 
I194S 
 
- I194T 
580-agc  
inhA4-7b 
580-atc 
I194N 
 
- I194T 
580-aac  
inhA4-8b - NS 
 
- - 
 
inhA4-9b - NS 
 
- - 
 
inhA4-10b - NS 
 
- - 
  
*Mutation reported is the amino acid present in M. tuberculosis 
Silent mutations indicated in gray text; NS, not sequenced; NM, no mutation 
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Table A6. Results of sequencing of pKM402 gyrAa survivor isolates 
Survivor 
Isolate 
Survivor Mutation  Established  Isolate 
Nucleotide Amino Acid  Laboratory Clinical 
gyrAa-1 
280-gac 
D95A 
 
D94N* D94A, G, H, N, Y 
280-ggc  
gyrAa-2 
280-gac 
D95Y 
 
D94N D94A, G, H, N, Y 
280-tac  
gyrAa-3 
280-gac 
D95N 
 
D94N D94A, G, H, N, Y 
280-aac  
gyrAa-4 
280-gac 
D95Y 
 
D94N D94A, G, H, N, Y 
280-tac  
gyrAa-5 
280-gac 
D95N 
 
D94N D94A, G, H, N, Y 
280-aac  
gyrAa-6 
280-gac 
D95Y 
 
D94N D94A, G, H, N, Y 
280-tac  
gyrAa-7 
280-gac 
D95N 
 
D94N D94A, G, H, N, Y 
280-aac  
gyrAa-8 
280-gac 
D95Y 
 
D94N D94A, G, H, N, Y 
280-tac  
gyrAa-9 
280-gac 
D95A 
 
D94N D94A, G, H, N, Y 
280-gcc  
gyrAa-10 
280-gac 
D95N 
 
D94N D94A, G, H, N, Y 
280-aac   
*There is an accepted inconsistency in the numbering system for gyrA (Maruri et 
al., 2012) 
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